CDIO צמיחה צפויה ברווח נקי למניה השנה Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics is developing AI-driven cardiac diagnostics by implementing Epi+Gen CHD tests for US clinics. The annual earnings per share growth profile featured on GURU.Markets demonstrates capital dynamics, where 0.00 represents the current metric level. Efficient express delivery of kits reduces operating expenses; however, limited insurance coverage forces the company to maintain affordable pricing for its innovative services.

Cardio Diagnostics maintains a unique niche thanks to its patented genetic markers for cardiac risk assessment. By analyzing year-over-year EPS growth percentages, an investor can observe the earnings per share trend relative to the previous period, allowing for an assessment of the business's scaling pace. A steady rise in this indicator confirms the method's recognition by insurance companies, whereas sharp spikes signal market overheating.